184 related articles for article (PubMed ID: 36596381)
21. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X
Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227
[TBL] [Abstract][Full Text] [Related]
22. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
23. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
[TBL] [Abstract][Full Text] [Related]
24. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
[TBL] [Abstract][Full Text] [Related]
25. Development of a neutralization monoclonal antibody with a broad neutralizing effect against SARS-CoV-2 variants.
Ko HL; Lee DK; Kim Y; Jang HJ; Lee YW; Lee HY; Seok SH; Park JW; Limb JK; On DI; Yun JW; Lyoo KS; Song D; Yeom M; Lee H; Seong JK; Lee S
Virol J; 2023 Dec; 20(1):285. PubMed ID: 38041113
[TBL] [Abstract][Full Text] [Related]
26. Genomic Epidemiology and Serology Associated with a SARS-CoV-2 R.1 Variant Outbreak in New Jersey.
Mathema B; Chen L; Wang P; Cunningham MH; Mediavilla JR; Chow KF; Luo Y; Zhao Y; Composto K; Zuckerman J; Zody MC; Wilson N; Lee A; Oschwald DM; Liu L; Iketani S; Germer S; Fennessey S; Wang M; Kramer Y; Toole P; Maniatis T; Ho DD; Perlin DS; Kreiswirth BN
mBio; 2022 Oct; 13(5):e0214122. PubMed ID: 35997285
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of the combination of monoclonal antibodies against the SARS-CoV-2 Beta and Delta variants.
Boonkrai C; Cotrone TS; Chaisuriyong W; Tantawichien T; Thisyakorn U; Fernandez S; Hunsawong T; Reed M; Wongtangprasert T; Audomsun T; Phakham T; Attakitbancha C; Saelao P; Focht D; Kimbung R; Welin M; Malik AA; Pisitkun T; Srisawat N
PLoS One; 2023; 18(5):e0284173. PubMed ID: 37141227
[TBL] [Abstract][Full Text] [Related]
28. Generation and Characterization of a Multi-Functional Panel of Monoclonal Antibodies for SARS-CoV-2 Research and Treatment.
Patterson LD; Dubansky BD; Dubansky BH; Stone S; Kumar M; Rice CD
Viruses; 2023 Dec; 16(1):. PubMed ID: 38257764
[TBL] [Abstract][Full Text] [Related]
29. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
30. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
[TBL] [Abstract][Full Text] [Related]
31. Neutralizing and enhancing monoclonal antibodies in SARS-CoV-2 convalescent patients: lessons from early variant infection and impact on shaping emerging variants.
Coutant F; Touret F; Pin JJ; Alonzo M; Baronti C; Munier S; Attia M; de Lamballerie X; Ferry T; Miossec P
Emerg Microbes Infect; 2024 Dec; 13(1):2307510. PubMed ID: 38240255
[TBL] [Abstract][Full Text] [Related]
32. A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.
Wu X; Cheng L; Fu M; Huang B; Zhu L; Xu S; Shi H; Zhang D; Yuan H; Nawaz W; Yang P; Hu Q; Liu Y; Wu Z
Cell Rep; 2021 Oct; 37(3):109869. PubMed ID: 34644535
[TBL] [Abstract][Full Text] [Related]
33. Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes.
Fan C; Cohen AA; Park M; Hung AF; Keeffe JR; Gnanapragasam PNP; Lee YE; Gao H; Kakutani LM; Wu Z; Kleanthous H; Malecek KE; Williams JC; Bjorkman PJ
Immunity; 2022 Dec; 55(12):2419-2435.e10. PubMed ID: 36370711
[TBL] [Abstract][Full Text] [Related]
34. Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein.
Goo J; Jeong Y; Park YS; Yang E; Jung DI; Rho S; Park U; Sung H; Park PG; Choi JA; Seo SH; Cho NH; Lee H; Lee JM; Kim JO; Song M
Virus Res; 2020 Mar; 278():197863. PubMed ID: 31945421
[TBL] [Abstract][Full Text] [Related]
35. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
[TBL] [Abstract][Full Text] [Related]
36. Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD.
Peter AS; Grüner E; Socher E; Fraedrich K; Richel E; Mueller-Schmucker S; Cordsmeier A; Ensser A; Sticht H; Überla K
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897753
[TBL] [Abstract][Full Text] [Related]
37. Novel neutralizing mouse-human chimeric monoclonal antibodies against the SARS-CoV-2 receptor binding domain.
Ghorbani A; Maghsood F; Yadegari H; Bahadori T; Zarnani AH; Razavi SA; Jeddi-Tehrani M; Amiri MM; Shokri F
J Med Microbiol; 2023 Jun; 72(6):. PubMed ID: 37387700
[No Abstract] [Full Text] [Related]
38. An efficient approach for SARS-CoV-2 monoclonal antibody production via modified mRNA-LNP immunization.
Hsu FF; Liang KH; Kumari M; Chen WY; Lin HT; Cheng CM; Tao MH; Wu HC
Int J Pharm; 2022 Nov; 627():122256. PubMed ID: 36198358
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants.
Wu WL; Chiang CY; Lai SC; Yu CY; Huang YL; Liao HC; Liao CL; Chen HW; Liu SJ
JCI Insight; 2022 Apr; 7(8):. PubMed ID: 35290246
[TBL] [Abstract][Full Text] [Related]
40. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
